仿制药在美国和印度的生产及使用情况对中国的启示  

Thoughts for China based on Generic Medicine Use in the USA and India

作　　者：吴久鸿[1] 李洪[2,3] WU Jiu-hong ,LI Hong

机构地区：[1]中国人民解放军第306医院,中国北京100101 [2]中国上海交通大学公共卫生学院,中国上海200025 [3]美国辛辛那提大学药学院

出　　处：《中国药物经济学》2018年第7期107-115,共9页China Journal of Pharmaceutical Economics

摘　　要：为进一步提高药品在中国的可及性,减轻医疗费用,中国政府最近在大力提倡生产和使用仿制药品。本文通过查阅相关文献,比较深入地描述了仿制药品在美国和印度的使用情况。以此为基础,笔者对中国在生产和使用仿制药品方面提出了一些思考和建议,同时也对如何使中国朝着成为生产创新药品大国的方向前进提出了浅见。To further improve medicine accessibility and reduce medical costs, China government is recently promoting production and use of generic medicines in the country. Through a careful review of published information this paper describes the situations of generic medicine use in the United States and in India. Based on the information authors of this paper share their views on how generic medicines should be produced and used in China .Furthermore authors also provide their view on how to make China to be a country with a strong capacity of research and development, production of innovative medicines in the world .

关 键 词：中国 美国 印度 仿制药品 创新药品 质量 一致性评价 GMP 

分 类 号：F426.72[经济管理—产业经济]